Clinical application of NMP22 and urinary cytology in patients with hematuria or a history of urothelial carcinoma

World Journal of Urology

Volumn 18, Issue 6, 2000, Pages 401-405

  Lee, Ming Yuan ^a   Tsou, Mei Hua ^a   Cheng, Mary H ^b   Chang, Daniel S ^a   Yang, Alex Lien Yen ^a   Ko, Jen Shene ^b  

^a KOO FOUNDATION SUN YAT SEN CANCER CENTER   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEAR MATRIX PROTEIN 22; NUCLEAR PROTEIN;

ARTICLE; BLADDER TUMOR; COMPARATIVE STUDY; CYTOLOGY; EVALUATION; HEMATURIA; HUMAN; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; URINE; UROLOGIC EXAMINATION;

CARCINOMA, TRANSITIONAL CELL; DIAGNOSTIC TECHNIQUES, UROLOGICAL; HEMATURIA; HUMANS; NUCLEAR PROTEINS; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS; URINE;

EID: 0034572643     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003450000124     Document Type: Article

References (21)

1. Abel PD (1998) Prognostic indices in transitional cell carcinoma of the bladder. Br J Urol 62: 103
2. Badalament RA, Hermansen DK, Kimmel M, Gay H, Herr HW, Fair WR, Whitmore WF, Melamed MR (1987) The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer 60: 1423-1427
3. Berezney R, Coffey DS (1974) Identification of a nuclear protein matrix. Biochem Biophys Res Commun 60: 1410-1417
4. Carpinito GA, Stadler WM, Briggman JV, Chod GW, Church PA, Lamm DL, Lange PH, Messing EM, Pasciak RM, Reservitz GB, Ross RN, Rukstalis DB, Sarosdy MF, Soloway MS, Thiel RP, Vogelzang N, Hayden CL (1996) Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol 156: 1280-1285
5. Chen Y, Hayden CL, Marchand KJ, Makuch RW (1997) Comparison of urine collection methods for evaluating urinary nuclear matrix protein, NMP22, as a tumor marker. J Urol 158: 1899-1901
6. Ellis WJ, Blumenstein BA, Ishak LM, Enfield DL (1997) Clinical evaluation of the BTA TRAK assay and comparison to void urinary cytology and the BARD BTA test in patients with recurrent bladder tumors. The Multiple Center Study Group. Urology 50: 882-887
7. Grossman HB (1998) New methods for detection of bladder cancer. Semin Urol Oncol 16: 17-22
8. Heicappell R, Wettig 1C, Schostak M, Muller M, Steiner U, Sauter T, Miller K (1999) Quantitative detection of human complement factor H-related protein in transitional cell carcinoma of the urinary bladder. Eur Urol 35: 81-87
9. International Union Against Cancer (1982) TNM classification of malignant tumours, 3rd edn. Springer, New York Berlin Heidelberg
10. Irani J, Desgrandchamps F, Millet C, Toubert ME, Bon D, Aubert J, Le Duc A (1999) BTA stat and BTA TRAK: a comparative evaluation of urine testing for the diagnosis of transitional cell carcinoma of the bladder. Eur Urol 35: 89-92
11. Kalaver E, Landman J, Chang Y, Droller MJ, Liu BC (1998) Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity. Cancer 82: 708-714
12. Landman J, Chang Y, Kavaler E, Droller MJ, Liu BC (1998) Sensitivity and specificity of NMP22, telomerase, and BTA in the detection of human bladder cancer. Urology 52: 398-402
13. Sarosdy MF, deVere RW, Soloway MS, Sheinfeld J, Hudson MA, Schellhammer RF, Jarowenko MV, Adams G, Blumenstein BA (1995) Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 154: 379-384
14. Sarosdy MF, Hudson MA, Ellis WJ, Soloway MS (1997) Improved detection of recurrent bladder cancer using the bard BTA stat test. Urology 50: 349-353
15. Schmetter S, Habicht K.K, Morales LA, Bander NH, Grossman HB. Hanna MG Jr, Silberman SR, Butman BT (1997) A multicenter trial evaluation of the fibrin/fibrinogen degradation products [tjrest for detection and monitoring of bladder cancer. J Urol 158: 801-805
16. Serretta V, Presti DL, Vasile P, Gange E, Esposito E, Menozzi I (1998) Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients. Urology 52: 793-796
17. Shelfo SW, Soloway MS (1997) The role of nuclear matrix protein 22 in the detection of persistent or recurrent transitional-cell cancer of the bladder. World J Urol 15: 107-111
18. Soloway MS, Briggman JV, Carpinito GA, Chodak GW, Church PA, Lamm DL, Lang P, Messing E, Pasciak RM, Reservitz GB, Rukstalis DB, Sarosdy MF, Stadier WM, Thiel RP, Hayden CL (1996) Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 156: 363-367
19. Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, Willsey LW, Dinney CP, Grossman HB, Pritsche HA, McDougal WS (1998) Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 159: 394-398
20. Wiener HG, Vooijs GP, Van't Hof-Grootenboer B (1993) Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer. Acta Cytol (Baltimore) 37: 163-169
21. Witjes J A, Van der Poel HG, Van Balken MR, Debruyne FM J, Schalken JA (1998) Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer. Fur Urol 33: 387-391